Glucuronidase: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 10: Line 10:


== Relevance ==
== Relevance ==
Deficiencies in the human form of &beta;-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>, PDB ID 3HN3) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII).  This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints.  As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.
Deficiencies in the human form of &beta;-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>, PDB ID 3HN3<ref>DOI:10.2210/pdb3hn3/pdb</ref>) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII).  This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints.  As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.


The ''E. coli'' form of &beta;-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>, PDB ID 3LPF) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11.  This drug gets converted to SN38, a topoisomerase inhibitor, by the liver.  The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine.  Once in the intestine, bacterial &beta;-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen.  The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.
The ''E. coli'' form of &beta;-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>, PDB ID 3LPF<ref>DOI:10.2210/pdb3lpf/pdb</ref>) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11.  This drug gets converted to SN38, a topoisomerase inhibitor, by the liver.  The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine.  Once in the intestine, bacterial &beta;-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen.  The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.


Selective inhibition of bacterial &beta;-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.
Selective inhibition of bacterial &beta;-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.
Line 26: Line 26:
</StructureSection>
</StructureSection>
== References ==
== References ==
<ref>DOI:10.2210/pdb3hn3/pdb</ref>
<ref>DOI:10.2210/pdb3hn3/pdb</ref>
<ref>DOI:10.2210/pdb3lpf/pdb</ref>

Revision as of 16:08, 6 August 2014

β-Glucuronidase

Ribbon diagram of humanβ-glucuronidase

Drag the structure with the mouse to rotate

References

[1] [2]

Proteopedia Page Contributors and Editors (what is this?)

Kimberly Lane, Michal Harel, Alexander Berchansky